The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer

Clinical Lung Cancer

Volumn 12, Issue 1, 2011, Pages 26-32

  Mahtani, Reshma ^a   Khan, Raza ^b   Jahanzeb, Mohammad ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b Canton Medical Education Foundation   (United States)

Author keywords

Bisphosphonates; Bone metastases

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOPLATIN; CISPLATIN; CLODRONIC ACID; COLECALCIFEROL; DOCETAXEL; DOXORUBICIN; GEFITINIB; IBANDRONIC ACID; IBUPROFEN; PACLITAXEL; PAMIDRONIC ACID; PARACETAMOL; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BONE METASTASIS; BONE PAIN; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; CELL INVASION; CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; HUMAN; HYPOCALCEMIA; IMMUNOMODULATION; JAW OSTEONECROSIS; KIDNEY FAILURE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; REVIEW; TUMOR GROWTH;

EID: 79551533439     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.3816/CLC.2011.n.003     Document Type: Review

References (49)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Tsuya A, Kurata T, Tamura K, et al. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007;57:229-32.
3. De Marinis F, Eberhardt W, Harper PG, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 2009;4:1280-8.
4. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
5. Passlick B. Micrometastases in non-small cell lung cancer (NSCLC). Lung Cancer 2001;34(suppl 3):S25-9.
6. Sienel W, Mecklenburg I, Dango S, et al. Detection of MAGE-A transcripts in bone marrow is an independent prognostic factor in operable non-small-cell lung cancer. Clin Cancer Res 2007;13:3840-7.
7. Brunsvig PF, Flatmark K, Aamdal S, et al. Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients. Lung Cancer 2008;61:170-6.
8. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42.
9. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998;19:18-54.
10. van Beek E, Pieterman E, Cohen L, et al. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 1999;255:491-4.
11. Zometa (zoledronic acid) injection [prescribing information]: East Hanover, NJ: Novartis Pharmaceuticals Corporation; revised October 2009.
12. Polascik TJ. Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Devel Ther 2009;3:27-40.
13. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21.
14. Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008;113:1438-45.
15. Hatoum HT, Lin S, Lipton A, et al. Persistency on monthly zoledronic acid impacts risk and frequency of skeletal complications and follow-up duration in lung cancer patients [poster discussion]. Presented at: 13th World Conference on Lung Cancer; July 31-August 4, 2009; San Francisco, CA. PD2.1.3.
16. Hirsh V. Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer. Clin Lung Cancer 2009;10:223-9.
17. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008;113:193-201.
18. Berger W, Kubista B, Elbling L, et al. The N-containing bisphosphonate zoledronic acid exerts potent anticancer activity against non-small cell lung cancer cells by inhibition of protein geranylgeranylation. Proc Am Assoc Cancer Res 2005;46: (abstract 4981).
19. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-54.
20. Denoyelle C, Hong L, Vannier JP, et al. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and-independent effects. Br J Cancer 2003;88:1631-40.
21. Ory B, Heymann MF, Kamijo A, et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005;104:2522-9.
22. Li YY, Chang JW, Chou WC, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 2008;59:180-91.
23. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61.
24. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-44.
25. Landmeier S, Altvater B, Pscherer S, et al. Presentation of Epstein Barr virus (EBV) epitopes by activated human γδ T cells induces peptide-specific cytolytic CD8+ T cell expansion. Blood 2006;108: (abstract 1738).
26. Fournier PG, Chirgwin JM, Guise TA. New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatol 2006;18:396-404.
27. Mattarollo SR, Kenna T, Nieda M, et al. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer Immunol Im-munother 2007;56:1285-97.
28. Ozturk OH, Bozcuk H, Burgucu D, et al. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study. Cell Biol Int 2007;31:1069-71.
29. Ottewell PD, Deux B, Monkkonen H, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 2008;14:4658-66.
30. Lu S, Zhang J, Zhou Z, et al. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. Oncol Rep 2008;20:581-7.
31. Gjyrezi A, O'Brate A, Chanel-Vos C, et al. Zoledronic acid synergizes with Taxol in an HDAC6-dependent manner: novel mechanistic implications for combination anticancer therapy with taxanes [abstract]. Presented at: The 98th Annual Meeting of the American Association for Cancer Research; April 14-18, 2007; Los Angeles, CA. Abstract 1425.
32. Chang JW, Hsieh JJ, Shen YC, et al. Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells. Cancer Lett 2009;278:17-26.
33. Knight LA, Kurbacher CM, Glaysher S, et al. Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosen-sitivity assay. BMC Cancer 2009;9:38.
34. Knight LA, Conroy M, Fernando A, et al. Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosen-sitivity assay. Anticancer Drugs 2005;16:969-76.
35. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8:1080-4.
36. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003;9:2893-7.
37. Bhattacharyya GS, Malhotra H, Agarwalla D. Amino bisphosphonate as a modulator for angiogenesis in lung cancer: Schedule dependent dosing [poster]. Presented at: The 13th World Conference on Lung Cancer; July 31-August 4, 2009; San Francisco, CA. Poster P2.160.
38. Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008;3:228-36.
39. Mystakidou K, Katsouda E, Parpa E, et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005;22:195-201.
40. Zarogoulidis K, Boutsikou E, Zarogoulidis P, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009;125:1705-9.
41. Pandya KJ, Gajra A, Warsi GM, et al. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer 2010;67:330-8.
42. Scagliotti G, Manegold C, De Marinis F, et al. Evaluating the efficacy of zoledronic acid for the prevention of disease progression in patients with non-small cell lung cancer. Presented at: ECCO 15 and 34th ESMO Multidisciplinary Congress. 20-24 September 2009; Berlin, Germany. Abstract P-9056.
43. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009;9:77-85.
44. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-91.
45. Morgan GJ, Davies FE, Gregory WM, et al. On behalf of the National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989-1999.
46. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphospho-nates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19:420-32.
47. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91.
48. Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009;20:137-45.
49. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826-36.